Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 1/20 | 0.54 |
| ▸ | PTGDR2 | Q9Y5Y4 | 1/20 | 0.50 |
| ▸ | FFAR4 | Q5NUL3 | 6/20 | 0.49 |
| ▸ | MEN1 | O00255 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
| ▸ | FFAR1 | O14842 | 9/20 | 0.46 |
| ▸ | KMO | O15229 | 1/20 | 0.45 |
| ▸ | FFAR2 | O15552 | 1/20 | 0.43 |
| ▸ | CYSLTR2 | Q9NS75 | 1/20 | 0.43 |
| ▸ | CYSLTR1 | Q9Y271 | 1/20 | 0.43 |
| ▸ | ANO1 | Q5XXA6 | 1/20 | 0.43 |
| ▸ | PPARG | P37231 | 1/20 | 0.42 |
| ▸ | PPARD | Q03181 | 1/20 | 0.42 |
| ▸ | PPARA | Q07869 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28875429 | 0.88 | MEN1 (0.44) | POLBPTGDR2FFAR4MEN1KMT2A | |
| SCHEMBL584750 | 0.87 | FFAR1 (0.54) | POLBPTGDR2FFAR4FFAR1 | |
| SCHEMBL3135089 | 0.84 | RXRA (0.53) | MEN1KMT2AANO1 | |
| SCHEMBL15094094 | 0.83 | POLQ (0.51) | PTGDR2FFAR4FFAR1KMOPPARD | |
| SCHEMBL30151142 | 0.83 | IDO1 (0.49) | PTGDR2FFAR4FFAR1KMOFFAR2 | |
| SCHEMBL3685960 | 0.82 | PTGDR2 (0.49) | PTGDR2FFAR4FFAR1KMOFFAR2 | |
| SCHEMBL4007916 | 0.82 | FFAR1 (0.58) | PTGDR2FFAR4FFAR1KMO | |
| SCHEMBL1207452 | 0.80 | CES2 (0.50) | PTGDR2FFAR4FFAR1KMOFFAR2 | |
| SCHEMBL34475543 | 0.80 | CES2 (0.50) | PTGDR2FFAR4FFAR1KMOFFAR2 | |
| SCHEMBL4596931 | 0.80 | FFAR4 (0.49) | FFAR4MEN1KMT2AFFAR1PPARG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-102557971-B | Substituted acids for the treatment of respiratory diseases | ASTRAZENECA AB | 2015-06-17 | — | — | CN | disclosed |
| EP-1765768-B1 | SUBSTITUTED ACIDS FOR THE TREATMENT OF RESPIRATORY DISEASES | ASTRAZENECA AB (SE) | 2013-11-06 | — | — | EP | disclosed |
| CN-102557971-A | Substituted acids for the treatment of respiratory diseases | ASTRAZENECA AB | 2012-07-11 | — | — | CN | disclosed |
| CN-101014564-B | Substituted acids for the treatment of respiratory diseases | ASTRAZENECA AB | 2012-05-09 | — | — | CN | disclosed |
| US-8022248-B2 | 3-[2-(3-Cyanophenoxy)-4-(trifluoromethyl)phenyl]propanoic acid;prostaglandin D2 inhibitor, orphan receptor CRTH2 antagonist; antiinflammatory, analgesic, antipyretic; respiratory system disorders: asthma and rhinitis; coupling amino/thio-phenyl derivatives with ester followed by hydrolysis to acid | ASTRAZENECA AB (SE) | 2011-09-20 | — | — | US | disclosed |
| US-20080114002-A1 | Substituted Acids for the Treatment of Respiratory Diseases | ASTRAZENECA AB (SE) | 2008-05-15 | — | — | US | disclosed |
| EP-1765768-A1 | SUBSTITUTED ACIDS FOR THE TREATMENT OF RESPIRATORY DISEASES | AstraZeneca AB (SE) | 2007-03-28 | — | — | EP | disclosed |
| WO-2006005909-A1 | SUBSTITUTED ACIDS FOR THE TREATMENT OF RESPIRATORY DISEASES | ASTRAZENECA AB (SE) | 2006-01-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080114002-A1 | Substituted Acids for the Treatment of Respiratory Diseases | HRH2, HRH1, HRH4 | POLB 2888/4885PTGDR2 176/4885FFAR4 133/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.